Overview

Neuropeptide Therapy of Recent Onset Type 1 Diabetes

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the delivery of substance P via the celiac artery in the treatment of recent onset type 1 diabetes.
Phase:
Phase 1
Details
Lead Sponsor:
Vanilloid Genetics Inc.
Treatments:
Neurokinin A
Substance P